Prediction Model of Long-term Survival After Esophageal Cancer Surgery

被引:17
作者
Xie, Shao-Hua [1 ]
Santoni, Giola [1 ]
Malberg, Kalle [1 ]
Lagergren, Pernilla [1 ,2 ]
Lagergren, Jesper [1 ,3 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Dept Mol Med & Surg, Stockholm, Sweden
[2] Imperial Coll London, Fac Med, Dept Surg & Canc, London, England
[3] Kings Coll London, Sch Canc & Pharmaceut Sci, London, England
基金
瑞典研究理事会;
关键词
esophageal neoplasms; mortality; prediction model; prognosis; surgery; survival; NEOADJUVANT CHEMORADIOTHERAPY; IMPACT; ADENOCARCINOMA; CHEMOTHERAPY; BENEFIT; RECURRENCE; EXPRESSION; MORBIDITY; CARCINOMA; NOMOGRAM;
D O I
10.1097/SLA.0000000000003431
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: We aimed to develop prediction models for estimating the long-term survival in patients who have undergone surgery for esophageal cancer. Background: Few prediction models have been developed for the long-term survival in esophageal cancer patients. Methods: This nationwide Swedish population-based cohort study included 1542 patients who survived for >= 90 days after esophageal cancer surgery between 1987 and 2010, with follow-up until 2016. Risk prediction models for 1-, 3-, and 5-year all-cause mortality and 3- and 5-year disease-specific mortality were developed using logistic regression. Candidate predictors were established and readily identifiable prognostic factors. The performance of the models was assessed by the area under receiver-operating characteristic curve (AUC) with interquartile range (IQR) using bootstrap cross-validation and risk calibration. Results: Predictors included in all models were age, sex, pathological tumor stage, tumor histology, and resection margin status. The models also included various additional predictors depending on the outcome, that is, education level, neoadjuvant therapy, reoperation (within 30 d of primary surgery) and comorbidity (Charlson comorbidity index). The AUC statistics after cross-validation were 0.71 (IQR 0.69-0.74) for 1-year, 0.77 (IQR 0.75-0.80) for 3-year, and 0.78 (IQR 0.76-0.81) for 5-year all-cause mortality. The corresponding values were 0.76 (IQR 0.74-0.79) for 3-year and 0.77 (IQR 0.71-0.83) for 5-year disease-specific mortality. All models showed good agreement between the observed and predicted risks. Conclusions: These models showed good performance for predicting long-term survival after esophageal cancer surgery and may thus be useful for patients in planning their lives and to guide the postoperative treatment and follow-up.
引用
收藏
页码:933 / 939
页数:7
相关论文
共 37 条
[1]   Recurrence after Esophagectomy for Adenocarcinoma: Defining Optimal Follow-Up Intervals and Testing [J].
Abate, Emmanuele ;
DeMeester, Steven R. ;
Zehetner, Joerg ;
Oezcelik, Arzu ;
Ayazi, Shahin ;
Costales, Jesse ;
Banki, Farzaneh ;
Lipham, John C. ;
Hagen, Jeffrey A. ;
DeMeester, Tom R. .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2010, 210 (04) :428-435
[2]   Impact of co-morbidity on mortality after oesophageal cancer surgery [J].
Backemar, L. ;
Lagergren, P. ;
Johar, A. ;
Lagergren, J. .
BRITISH JOURNAL OF SURGERY, 2015, 102 (09) :1097-1105
[3]   The Swedish cause of death register [J].
Brooke, Hannah Louise ;
Talback, Mats ;
Hornblad, Jesper ;
Johansson, Lars Age ;
Ludvigsson, Jonas Filip ;
Druid, Henrik ;
Feychting, Maria ;
Ljung, Rickard .
EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2017, 32 (09) :765-773
[4]   The Charlson Comorbidity Index in Registry-based Research Which Version to Use? [J].
Brusselaers, Nele ;
Lagergren, Jesper .
METHODS OF INFORMATION IN MEDICINE, 2017, 56 (05) :401-406
[5]   Association between Education Level and Prognosis after Esophageal Cancer Surgery: A Swedish Population-Based Cohort Study [J].
Brusselaers, Nele ;
Mattsson, Fredrik ;
Lindblad, Mats ;
Lagergren, Jesper .
PLOS ONE, 2015, 10 (03)
[6]   Tumor Stage After Neoadjuvant Chemotherapy Determines Survival After Surgery for Adenocarcinoma of the Esophagus and Esophagogastric Junction [J].
Davies, Andrew R. ;
Gossage, James A. ;
Zylstra, Janine ;
Mattsson, Fredrik ;
Lagergren, Jesper ;
Maisey, Nick ;
Smyth, Elizabeth C. ;
Cunningham, David ;
Allum, William H. ;
Mason, Robert C. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) :2983-+
[7]   Hospital and Surgeon Volume in Relation to Survival After Esophageal Cancer Surgery in a Population-Based Study [J].
Derogar, Maryam ;
Sadr-Azodi, Omid ;
Johar, Asif ;
Lagergren, Pernilla ;
Lagergren, Jesper .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (05) :551-557
[8]   Prognostic Value of Changes in Health-Related Quality of Life Scores During Curative Treatment for Esophagogastric Cancer [J].
Djaerv, Therese ;
Metcalfe, Chris ;
Avery, Kerry N. L. ;
Lagergren, Pernilla ;
Blazeby, Jane M. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (10) :1666-1670
[9]   Nomogram for Predicting the Benefit of Neoadjuvant Chemoradiotherapy for Patients With Esophageal Cancer A SEER-Medicare Analysis [J].
Eil, Robert ;
Diggs, Brian S. ;
Wang, Samuel J. ;
Dolan, James P. ;
Hunter, John G. ;
Thomas, Charles R. .
CANCER, 2014, 120 (04) :492-498
[10]   Impact of pre-diagnosis behavior on risk of death from esophageal cancer: a systematic review and meta-analysis [J].
Fahey, Paul P. ;
Mallitt, Kylie-Ann ;
Astell-Burt, Thomas ;
Stone, Glenn ;
Whiteman, David C. .
CANCER CAUSES & CONTROL, 2015, 26 (10) :1365-1373